Nomination Summary for Cimetidine (N91221)
Nominated Substances: Cimetidine
Nomination Date: 03/11/1991
Nominator: Private Individual
Rationale: This commonly used gastric acid inhibitor appears to increase SCE frequency in ulcer patients and following in-vitro incubation of human lymphocytes. It also produces chromosomal aberrations in rodent models. Inadequate testing for carcinogenicity.
NTP Principles: not specified
Status: In Review/Pending